An Escalating Dose, Randomized, Placebo-controlled, Incomplete-block, 2-period Cross-over Study to Assess the Dose Response for Topical Efficacy Via Airway Responsiveness to Adenosine-5'-Monophosphate (AMP) Challenge and the Dose Response for Systemic Activity Via 24h Plasma Cortisol Suppression and Thereby the Relative Therapeutic Index for Fluticasone Furoate (FF), Fluticasone Propionate (FP) and Budesonide (BUD) in Asthmatic Subjects
Latest Information Update: 26 Aug 2022
At a glance
- Drugs Budesonide (Primary) ; Fluticasone furoate (Primary) ; Fluticasone propionate (Primary)
- Indications Asthma
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 15 Aug 2022 Results assessing toidentify dose-related systemic effects of inhaled glucocorticoids (GCs) on the global metabolome, published in the European Journal of Endocrinology.
- 02 Jun 2020 Results published in the British Journal of Clinical Pharmacology
- 25 Jan 2019 Status changed from recruiting to completed.